Bruton's TK inhibitors: structural insights and evolution of clinical candidates
- PMID: 24895895
- DOI: 10.4155/fmc.14.24
Bruton's TK inhibitors: structural insights and evolution of clinical candidates
Abstract
Bruton's TK (BTK) is a promising biological target for therapeutic intervention of several diseases including inflammatory diseases and cancer/B cell malignancies. Numerous research groups are actively engaged in investigating the functions of BTK, and discovering potent and selective BTK inhibitors as drug candidates. Revealed by x-ray crystal structures with ligands of diverse chemical structures, the ability of BTK kinase domain to adopt various inactive conformations offers unique opportunities to identify highly potent and exquisitely selective inhibitors. Both reversible and covalent inhibitor approaches have yielded candidates demonstrating safety profiles and efficacies in multiple preclinical models of autoimmunity and oncology. Two BTK inhibitors have entered human clinical trials for oncology indications. Ibrutinib won the US FDA approval in November 2013 to become the first-in-class BTK inhibitor for treating mantle cell lymphoma. This encouraging outcome and the other on-going human studies could ultimately expand the utility of BTK inhibitors to broader autoimmune disease areas.
Similar articles
-
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.Eur J Med Chem. 2018 May 10;151:315-326. doi: 10.1016/j.ejmech.2018.03.062. Epub 2018 Mar 23. Eur J Med Chem. 2018. PMID: 29631132 Review.
-
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51. Future Oncol. 2014. PMID: 24941982 Free PMC article. Review.
-
Ibrutinib and novel BTK inhibitors in clinical development.J Hematol Oncol. 2013 Aug 19;6:59. doi: 10.1186/1756-8722-6-59. J Hematol Oncol. 2013. PMID: 23958373 Free PMC article. Review.
-
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.Arch Pharm (Weinheim). 2018 Jul;351(7):e1700369. doi: 10.1002/ardp.201700369. Epub 2018 May 9. Arch Pharm (Weinheim). 2018. PMID: 29741794 Review.
-
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.Future Med Chem. 2018 Feb;10(3):343-356. doi: 10.4155/fmc-2017-0145. Epub 2018 Jan 19. Future Med Chem. 2018. PMID: 29347836 Review.
Cited by
-
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.Elife. 2020 Nov 23;9:e60470. doi: 10.7554/eLife.60470. Elife. 2020. PMID: 33226337 Free PMC article.
-
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.ACS Med Chem Lett. 2017 May 3;8(6):608-613. doi: 10.1021/acsmedchemlett.7b00103. eCollection 2017 Jun 8. ACS Med Chem Lett. 2017. PMID: 28626519 Free PMC article.
-
Novel and emerging targeted-based cancer therapy agents and methods.Tumour Biol. 2015 Feb;36(2):543-56. doi: 10.1007/s13277-015-3184-x. Epub 2015 Feb 9. Tumour Biol. 2015. PMID: 25663495 Review.
-
Disrupting enzyme fluidity.Elife. 2021 Jan 25;10:e65221. doi: 10.7554/eLife.65221. Elife. 2021. PMID: 33492229 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
